313067-82-2

Upstream product

• 51388-20-6 4-benzyloxyaniline hydrochloride 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 

Downstream Products

• 757975-99-8 (E)-3-[4-((S)-2-{[1-(Biphenyl-3-ylamino)-cyclohexanecarbonyl]-amino}-butylamino)-phenoxy]-acrylic acid benzyl ester 
• 757975-93-2 tert-butyl {4-[((2S)-2-{[N-(2-oxo-6-phenyl-2H-pyran-4-yl)-L-leucyl]amino}butyl)amino]phenoxy}acetate 
• 757975-92-1 tert-butyl {4-[((2S)-2-{[N-(morpholin-4-ylcarbonyl)-L-leucyl]amino}butyl)amino]phenoxy}acetate 
• 757976-04-8 tert-butyl {4-[((2S)-2-{[N-(5-phenylisoxazol-3-yl)-L-leucyl]amino}butyl)amino]phenoxy}acetate 
• 757975-91-0 (S)-4-Methyl-2-(2-oxo-6-phenyl-2H-pyran-4-ylamino)-pentanoic acid {(S)-1-[(4-benzyloxy-phenylamino)-methyl]-propyl}-amide 
• 757976-03-7 (S)-4-Methyl-2-(5-phenyl-isoxazol-3-ylamino)-pentanoic acid {(S)-1-[(4-benzyloxy-phenylamino)-methyl]-propyl}-amide 
• 757975-90-9 Morpholine-4-carboxylic acid ((S)-1-{(S)-1-[(4-benzyloxy-phenylamino)-methyl]-propylcarbamoyl}-3-methyl-butyl)-amide 
• 757976-50-4 N¹-((1S)-1-{[(4-hydroxyphenyl)amino]methyl}propyl)-N²-(2-oxo-6-phenyl-2H-pyran-4-yl)-L-leucinamide 
• 757976-49-1 N-((1S)-1-{[(4-hydroxyphenyl)amino]methyl}propyl)-N²-[(morpholin-4-yl)carbonyl]-L-leucinamide 
• 757976-56-0 N¹-((1S)-1-{[(4-hydroxyphenyl)amino]methyl}propyl)-N²-(5-phenylisoxazol-3-yl)-L-leucinamide 
• 757975-82-9 [4-(2-{[1-(biphenyl-3-ylamino)-cyclohexanecarbonyl]-amino}-butylamino)-phenoxy]-acetic acid tert-butyl ester 
• 757975-81-8 1-(Biphenyl-3-ylamino)-cyclohexanecarboxylic acid {(S)-1-[(4-benzyloxy-phenylamino)-methyl]-propyl}-amide 
• 757975-87-4 tert-butyl {4-[((2S)-2-{[N-(biphenyl-3-yl)-L-leucyl]amino}butyl)amino]phenoxy}acetate 

Relevant academic research and scientific papers

Potent and selective cathepsin K inhibitors

A novel series of cathepsin K inhibitors derived from Novartis compound I is described. Optimization of the P1, P3, and P1′ units led to the identification of 4-aminophenoxyacetic acid 24b with an IC50 value of 4.8 nM, which possessed an excell

Arylamine based cathepsin K inhibitors: Investigating P3 heterocyclic substituents

A modification of novel cathepsin K inhibitors I was carried out. The structural design was aimed at reducing the lipophilic character of compounds I for obtaining better pharmacokinetic profiles. This modification afforded several less lipophilic compoun